Published in Tissue Eng Part C Methods on September 28, 2016
Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. Biotechnol Adv (2016) 0.79
Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes. J Cardiovasc Transl Res (2016) 0.79
Recapitulation of microtissue models connected with real-time readout systems via 3D printing technology. J Thorac Dis (2017) 0.75
IGF1 and NRG1 Enhance Proliferation, Metabolic Maturity, and the Force-Frequency Response in hESC-Derived Engineered Cardiac Tissues. Stem Cells Int (2017) 0.75
Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol (2007) 14.48
Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res (2011) 3.25
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol (2012) 2.50
Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood (1995) 2.40
Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res (2014) 2.34
Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J (1997) 2.33
Magnetic microposts as an approach to apply forces to living cells. Proc Natl Acad Sci U S A (2007) 2.10
Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip (2011) 2.02
Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation (2012) 1.98
Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials (2013) 1.97
A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng Part A (2012) 1.95
Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One (2011) 1.73
Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc Res (2011) 1.67
Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation (2013) 1.54
Magnetically actuated nanorod arrays as biomimetic cilia. Nano Lett (2007) 1.52
Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J (2010) 1.45
Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip (2013) 1.44
Cardiac grafting of engineered heart tissue in syngenic rats. Circulation (2002) 1.43
Engineered heart tissue for regeneration of diseased hearts. Biomaterials (2004) 1.36
Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol (2012) 1.31
Cardiac tissue engineering: state of the art. Circ Res (2014) 1.30
Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J (2011) 1.29
Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res (2013) 1.22
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J (2013) 1.15
Induced pluripotent stem (iPS) cells repair and regenerate infarcted myocardium. Mol Pharm (2011) 1.12
Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochem J (2011) 1.11
Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem (2009) 1.09
Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells Transl Med (2011) 1.09
Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep (2015) 1.04
Probing cellular traction forces by micropillar arrays: contribution of substrate warping to pillar deflection. Nano Lett (2010) 1.04
Contractile properties of early human embryonic stem cell-derived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev (2012) 1.01
Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods (2013) 0.96
Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol (2014) 0.92
Human Engineered Heart Tissue: Analysis of Contractile Force. Stem Cell Reports (2016) 0.92
Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells. J Mol Cell Cardiol (2015) 0.91
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. Adv Drug Deliv Rev (2015) 0.91
Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol (2014) 0.89
Mechanical Stress Promotes Maturation of Human Myocardium From Pluripotent Stem Cell-Derived Progenitors. Stem Cells (2015) 0.88
Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications. J Tissue Eng Regen Med (2010) 0.87
The effects of various drugs on the myocardial inotropic response. Gen Pharmacol (1995) 0.87
Cell therapy for cardiac regeneration after myocardial infarct: which cell is the best? Cardiovasc Hematol Agents Med Chem (2010) 0.86
High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicol Appl Pharmacol (2015) 0.85
Engineered cardiac tissues. Curr Opin Biotechnol (2011) 0.85
Modeling myocardial growth and hypertrophy in engineered heart muscle. Trends Cardiovasc Med (2013) 0.84
3D cardiac μtissues within a microfluidic device with real-time contractile stress readout. Lab Chip (2015) 0.82
Electrophysiology of calcium antagonists. J Mol Cell Cardiol (1987) 0.81
Generation of strip-format fibrin-based engineered heart tissue (EHT). Methods Mol Biol (2014) 0.79
Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. J Cardiovasc Pharmacol (1990) 0.78
Human engineered heart tissue as a model system for drug testing. Adv Drug Deliv Rev (2015) 0.78